A Randomized Phase II Study of Rituximab With ABVD Versus Standard ABVD for Patients With Advanced-Stage Classical Hodgkin Lymphoma With Poor Risk Features (IPS Score > 2).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Bleomycin (Primary) ; Dacarbazine (Primary) ; Doxorubicin (Primary) ; Rituximab (Primary) ; Vinblastine (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 04 Oct 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
- 03 Oct 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
- 29 Sep 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov.